in tumor, aminopeptidase N has been an appealing target for anti-tumor drug development. Here, a serial of novel aminopeptidase N inhibitors with L-arginine scaffold were designed, synthesized and evaluated for aminopeptidase N inhibitory activities. The preliminary anti-enzyme activity assay demonstrated that compounds 5e, 5h, 11e, 11g, and 11h showed comparable activities with the positive control
考虑到在肿瘤中发挥的重要作用,
氨肽酶N已成为
抗肿瘤药物开发的有吸引力的靶标。在这里,设计,合成和评估一系列新型的
L-精氨酸支架的
氨肽酶N
抑制剂的
氨肽酶N抑制活性。初步的抗酶活性测定表明,化合物5e,5h,11e,11g和11h显示出与阳性对照Bestatin(一种批准的
氨肽酶N
抑制剂)相当的活性。在体外抗增殖试验中,化合物5f对四种过表达
氨基肽酶N的肿瘤细胞显示出优异的活性。在体内抗转移试验中,化合物5f和11g表现出比Bestatin更好的活性。因此5f和11g应作为进一步开发的新型
氨基肽酶N
抑制剂的先导化合物。